3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
31
Neoplasms
18
Kidney Neoplasms
17
Neuroendocrine Tumors
16
Neoplasm Metastasis
13
Tuberous Sclerosis
10
Prostatic Neoplasms
8
Carcinoma
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large B-Cell, Diffuse
7
Hodgkin Disease
7
Glioma
7
Glioblastoma
7
Astrocytoma
7
Waldenstrom Macroglobulinemia
6
Triple Negative Breast Neoplasms
6
Recurrence
6
Lymphoma
6
Head and Neck Neoplasms
6
Stomach Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Neuroendocrine
5
Brain Neoplasms
5
Sezary Syndrome
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Mycosis Fungoides
4
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
Everolimus
×
Clear all
No trials found.